- Home
- NNOX vs TNXP Comparison
NNOX vs TNXP Comparison
Compare NNOX & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNOX
- TNXP
- Stock Information
- Founded
- NNOX 2011
- TNXP 2007
- Country
- NNOX Israel
- TNXP United States
- Employees
- NNOX N/A
- TNXP N/A
- Industry
- NNOX Medical Electronics
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- NNOX Health Care
- TNXP Health Care
- Exchange
- NNOX Nasdaq
- TNXP Nasdaq
- Market Cap
- NNOX 335.1M
- TNXP 272.0M
- IPO Year
- NNOX 2020
- TNXP N/A
- Fundamental
- Price
- NNOX $5.06
- TNXP $40.87
- Analyst Decision
- NNOX Strong Buy
- TNXP Strong Buy
- Analyst Count
- NNOX 2
- TNXP 2
- Target Price
- NNOX $9.50
- TNXP $585.00
- AVG Volume (30 Days)
- NNOX 1.0M
- TNXP 720.7K
- Earning Date
- NNOX 08-19-2025
- TNXP 08-15-2025
- Dividend Yield
- NNOX N/A
- TNXP N/A
- EPS Growth
- NNOX N/A
- TNXP N/A
- EPS
- NNOX N/A
- TNXP N/A
- Revenue
- NNOX $11,545,000.00
- TNXP $10,041,000.00
- Revenue This Year
- NNOX $23.81
- TNXP $11.66
- Revenue Next Year
- NNOX $149.38
- TNXP $793.18
- P/E Ratio
- NNOX N/A
- TNXP N/A
- Revenue Growth
- NNOX 15.32
- TNXP N/A
- 52 Week Low
- NNOX $3.75
- TNXP $6.76
- 52 Week High
- NNOX $11.00
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- NNOX 48.70
- TNXP 62.15
- Support Level
- NNOX $5.12
- TNXP $33.20
- Resistance Level
- NNOX $5.35
- TNXP $43.80
- Average True Range (ATR)
- NNOX 0.21
- TNXP 2.63
- MACD
- NNOX 0.00
- TNXP 0.31
- Stochastic Oscillator
- NNOX 66.15
- TNXP 77.43
About NNOX NANO-X IMAGING LTD
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.